Design
Review
Authors
Loading...
Supports ACE inhibitor use in most hypertension; leaves open mineralocorticoid exceptions and needs prospective trials.
The development of orally active ACE inhibitors like captopril represents a major clinical success in targeting the renin-angiotensin system for the treatment of hypertension.
Michael J. Antonaccio (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: